Cochrane · systematic review · CD010179
Addition of intravenous beta₂‐agonists to inhaled beta₂‐agonists for acute asthma
Travers, AH, Milan, SJ, Jones, AP, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
IV + inhaled beta agonist compared with inhaled beta‐agonist for acute asthma
Population: patients with acute asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Admissions to hospital IV + inhaled beta agonist vs inhaled beta‐agonist | OR 0.29 [0.06, 1.38] | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |
Length of stay in emergency department IV + inhaled beta agonist vs inhaled beta‐agonist | no estimate extracted | 1 study · 46 participants | Moderate Downgraded: risk of bias, imprecision |
Pulse rate at 2 hours IV + inhaled beta agonist vs inhaled beta‐agonist | MD 10 | 1 study · 29 participants | Moderate Downgraded: risk of bias, imprecision |
Clinical Failure (children with a severe to moderate overall clinical assessment score at two hours) IV + inhaled beta agonist vs inhaled beta‐agonist | OR 0.09 [0.02, 0.38] | 1 study · 29 participants | Moderate Downgraded: risk of bias, imprecision |